Medical Products Supply Chain Week in Review June 28, 2021

COVID-19 Medical Products Supply Chain Week in Review – June 28, 2021

Last week, the FDA added new heart health risk information to mRNA vaccines’ fact sheets. In addition, the U.S. seized unauthorized COVID-19 drugs en route from Bangladesh and India to Mexico. Please see details for these and other supply chain developments below:

  • On June 23, the Wall Street Journal reported that the U.S. government had seized at U.S. airports unauthorized versions of the COVID-19 treatment remdesivir, which were en route from Bangladesh and India to Mexico.
  • On June 24, the FDA issued an emergency use authorization (EUA) for Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
  • On June 24, President Biden announced that 66 percent of all American adults have received at least one shot of COVID-19 vaccine, including over 150 million Americans fully vaccinated.
  • On June 25, the FDA announced revisions to the patient and provider fact sheets for the Moderna and Pfizer/BioNTech COVID-19 vaccines to include information regarding risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination.

Please do not hesitate to contact us if you have any questions about these developments.

Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.